Trending...
- Governor Gavin Newsom signs SB 27, strengthening California's CARE Act and expanding access to behavioral health services
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
- Richline Transportation Expands Luxury Airport Transfer and Black Car Service in San Diego
SAN JOSE, Calif. - Californer -- CPC Scientific Inc. is pleased to announce that the Dutch Medicines Evaluation Board (MEB) has completed its technical review of their client's drug product and formulation process for Terlipressin. The API provided to the client is manufactured at CPC Scientific's GMP facility. On January 18, 2021, the MEB granted approval of the drug product and will move to the next phase to review product characterization profiles, specifications, and labels in the Netherlands. The MEB is the Dutch regulatory agency responsible for assessing, monitoring, and promoting the proper use of medicines. After final approval, the drug product will be available for sale in the Netherlands and Germany.
Comment from Shawn Lee, CEO and Founder of CPC Scientific Inc.
"We are thrilled with the outcome MEB's technical review of our terlipressin API being used in our partner's drug product. We are hopeful that this approval will lead to increased patient access to terlipressin in the Netherlands and Germany."
More on The Californer
Terlipressin, chemically known as triglycyl lysine vasopressin, is a synthetic long-acting vasopressin used for the emergency treatment of acute bleeding of esophageal varices and type 1 hepatorenal syndrome (characterized by spontaneous acute renal insufficiency) with severe cirrhosis of the liver and ascites. Terlipressin injection was first approved on September 23, 2010 in Europe a commercial product for use in Germany, the Netherlands, the United Kingdom, Spain and Italy. Current License holders for terlipressin include Ferring Pharmaceuticals (trade name Glypressin) and New Medicon Pharma (trade name Teripress).
About CPC Scientific Inc.
Founded in 2001, CPC Scientific is a globally recognized and leading CDMO specializing in synthetic peptide production. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. They boast the largest research peptide facility in the world, which successfully has undergone multiple FDA inspections and audits by global pharma organizations. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing. We provide milligram to multi-kilogram quantities of CGMP and research-grade peptides with purities of up to 99%. With their emphasis on technology, innovation, and experience, we are proud to have a US FDA inspected GMP facility, ISO 9001, and ISO 13485 certification, a claim few companies in the world can make.
More on The Californer
Inquiries:
CPC Scientific Inc.
Dr. Chris Gothard +1-408-734-3800 (San Jose, CA)
EMAIL: chris@cpcscientifc.com
Comment from Shawn Lee, CEO and Founder of CPC Scientific Inc.
"We are thrilled with the outcome MEB's technical review of our terlipressin API being used in our partner's drug product. We are hopeful that this approval will lead to increased patient access to terlipressin in the Netherlands and Germany."
More on The Californer
- City of Long Beach Introduces Interest Form to Connect Local Businesses and Property Owners with 2028 Games Stakeholders
- Six-Figure Chicks Book Series 96 Authors, 6 Volumes Published to Empower and Mentor Women Nationwide
- MTN WTR Partners with Sumo + Sushi 2025 U.S. Tour to Celebrate Japanese Culture Across Five Cities
- Hundreds of new homes for veterans are coming to California through voter-approved Prop 1 funding
- LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
Terlipressin, chemically known as triglycyl lysine vasopressin, is a synthetic long-acting vasopressin used for the emergency treatment of acute bleeding of esophageal varices and type 1 hepatorenal syndrome (characterized by spontaneous acute renal insufficiency) with severe cirrhosis of the liver and ascites. Terlipressin injection was first approved on September 23, 2010 in Europe a commercial product for use in Germany, the Netherlands, the United Kingdom, Spain and Italy. Current License holders for terlipressin include Ferring Pharmaceuticals (trade name Glypressin) and New Medicon Pharma (trade name Teripress).
About CPC Scientific Inc.
Founded in 2001, CPC Scientific is a globally recognized and leading CDMO specializing in synthetic peptide production. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. They boast the largest research peptide facility in the world, which successfully has undergone multiple FDA inspections and audits by global pharma organizations. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing. We provide milligram to multi-kilogram quantities of CGMP and research-grade peptides with purities of up to 99%. With their emphasis on technology, innovation, and experience, we are proud to have a US FDA inspected GMP facility, ISO 9001, and ISO 13485 certification, a claim few companies in the world can make.
More on The Californer
- California highlights earthquake preparedness for Great ShakeOut Day
- DALPS Announces Global Airdrop to Reward Users and Expand Its Offers Marketplace
- Governor Newsom expands response arsenal with new emergency services facility in Southern California
- ALYXX Features on Oceans In Silhouette "Under My Skin" Single
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
Inquiries:
CPC Scientific Inc.
Dr. Chris Gothard +1-408-734-3800 (San Jose, CA)
EMAIL: chris@cpcscientifc.com
Source: CPC Scientific Inc.
0 Comments
Latest on The Californer
- California: Governor Newsom calls for congressional investigation into vile, antisemitic and violent messages from MAGA organization
- Premier Workspaces Elevates Its San Francisco Presence at One Sansome Street
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- City of Long Beach Launches Local Hiring Preferences
- The Mogharebi Group Facilitates $34.6 Million Sale of Willow Grove Apartments in Modesto, CA
- UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
- Rachel Farris, CPA Named Among Forbes' Top CPAs in America
- California: Crime is down in San Francisco, key law enforcement partnerships yield successful results
- Scott St. Germain, U.S. Army Veteran and Vice President at Genentech, Joins Dream Foundation Board
- New West Symphony: E.T. The Extra-Terrestrial in Concert
- Vesper Public Relations is selected as an official supplier of the LASEC Business Connect Program
- California announces coalition of Governors forming new alliance to protect public health from political interference
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
- QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Inside the Practice of a Caring Dentist Bringing Personalized Care to La Jolla
- Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
- City of Long Beach Confirms First Case of Clade I Mpox